## AD / Tauopathy

## TMHT Transgenic Mouse Model

The TMHT (Thy1 Mutated Human Tau) mouse was developed in-house and is exclusively available at Scantox. TMHT mice overexpress the human TAU441 with two mutations, V337M and R406W under control of the neuron- specific murine Thy1 promoter.

- Cognitive deficits in the Morris water maze starting at 5 months of age
- No motor deficits
- Tau phosphorylation at Thr181, Ser202, Thr231/Ser235, Ser396/Ser404


## Figure 1:

Morris water maze escape latencies of 5 and 8 month old TMHT mice. Mean $\pm$ SEM; $\mathrm{n}=19$ - 54; Two-way ANOVA with Bonferroni's post hoc test; *p<0.05, ***p<0.01.

Figure 1


Figure 2

## soluble total tau

A


5 months

## Figure 2:

Quantitative analysis of
soluble and insoluble Tau
and ptau expression levels
in the hippocampus of 3 to
13 months old TMHT mice
compared to non-transgenic animals by MSD
immunosorbent assay.
A: Soluble total tau levels.
B: Soluble ptau Thr231
levels. $n=4-13$. Mean $\pm$
SEM. Two-way ANOVA
with Bonferroni's post hoc
test. ***p<0.001

## Figure 3:

Immuofluorescent of total tau (HT7) and ptau Thr231 (AT180) labeling in the amygdala of 2,6 and 12 months old TMHT mice.

Flunkert et al. Elevated Levels of Soluble Total and Hyperphosphorylated Tau Result in Early Behavioral Deficits and Distinct Changes in Brain Pathology in a New Tau Transgenic Mouse Model. Neurodegener Dis. 2012 Jul 10.

## 8 months



## Scantox

Discovery
Important note:
Representative data are shown
throughout this document. However, biological variability might cause deviations from shown data.

## Scantox Group, HQ

Hestehavevej 36A, Ejby
DK - 4623 Lille Skensved
clientservice@scantox.com
www.scantox.com
+45 56861500

## © Scantox A/S

Scantox is a registered
trademark of Scantox A/S.


